VETOQUINOL INH. EO 250
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more
VETOQUINOL INH. EO 250 (8JM) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, VETOQUINOL INH. EO 250 (8JM) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VETOQUINOL INH. EO 250 - Net Assets Trend (None–None)
This chart illustrates how VETOQUINOL INH. EO 250's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VETOQUINOL INH. EO 250 (None–None)
The table below shows the annual net assets of VETOQUINOL INH. EO 250 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to VETOQUINOL INH. EO 250's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
VETOQUINOL INH. EO 250 Competitors by Market Cap
The table below lists competitors of VETOQUINOL INH. EO 250 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Halfords Group plc
PINK:HLFDF
|
$293.64 Million |
|
One United Properties SA
RO:ONE
|
$293.67 Million |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
$293.70 Million |
|
Anhui Sunhere Pharmaceutical Excipients Co Ltd
SHE:300452
|
$293.70 Million |
|
Jiangyin Electrical Alloy Co Ltd
SHE:300697
|
$293.48 Million |
|
Jiayin Group Inc
NASDAQ:JFIN
|
$293.47 Million |
|
Leo Lithium Ltd
AU:LLL
|
$293.32 Million |
|
4iG Nyrt.
BUD:4IG
|
$293.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VETOQUINOL INH. EO 250's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares VETOQUINOL INH. EO 250's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently VETOQUINOL INH. EO 250 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares VETOQUINOL INH. EO 250's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VETOQUINOL INH. EO 250 (8JM) | €- | N/A | N/A | $293.61 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |